ATAI Investor Day Presentation Deck

RL - 007: a de-risked pro-cognitive treatment for CIAS De-risked pharma developed product in-licensed with impressive ($100M) pre-clinical & clinical data package Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects, consistent with broad pre-clinical pro-cognitive data Well tolerated (>500 subjects dosed), centrally acting oral drug Initial indication: Cognitive Impairment Associated with Schizophrenia (CIAS) is characterized by episodic learning and memory deficits -no approved treatment atai LIFE SCIENCES | 23

View entire presentation